TELCON RF PHARMACEUTICAL Paid-in Capital Increase
텔콘RF제약
200230
Signal Score
Historical Avg Return (5d)
+0.26%
Data Coverage
100%n=2473
Risk-adjusted indicator based on 2473 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Operating Funds: 3,999,999,736 KRW
- • Acquisition of Other Securities Funds: 1,000,000,000 KRW
- • Total Funding: 4,999,999,736 KRW
- • Evercore Investment Holdings Post-Increase Shareholding: 2,329,916 Shares (24.57%)
- • New Shares Lock-up Period: 1 year from share delivery date
AI Analysis Summary
TELCON RF PHARMACEUTICAL decided on a paid-in capital increase to raise 4,999,999,736 KRW. The funds will be allocated to operating expenses (3,999,999,736 KRW for raw material purchases) and acquisition of other securities (1,000,000,000 KRW). Post-issuance, Evercore Investment Holdings will become the largest shareholder with 2,329,916 shares (24.57%), replacing Newon. New shares will be subject to a one-year lock-up. While the capital increase provides necessary funding, the change in largest shareholder and the lack of specific details on the 'other securities acquisition' introduce some uncertainty.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.